不同给药方法在多囊卵巢综合征促孕治疗中的效果研究

doi:10.3760/cma.j.issn.1007-1245.2023.01.015

国际医药卫生导报 ›› 2023, Vol. 29 ›› Issue (1): 74-.DOI: 10.3760/cma.j.issn.1007-1245.2023.01.015

不同给药方法在多囊卵巢综合征促孕治疗中的效果研究

高建华¹ 王钏¹ 占明¹ 周莹² 刘芳兰¹

¹江西医学高等专科学校医学技术学院，上饶　334000；²上饶市人民医院中医科，上饶　334000

出版日期:2023-01-01 发布日期:2023-01-27
通讯作者: 高建华，Email：sky879100@163.com
基金资助:
江西省卫生健康委科技计划资助项目（202141025）

Study on the effects of different medication methods in the promoting pregnancy treatment of polycystic ovary syndrome

Gao Jianhua¹, Wang Chuan¹, Zhan Ming¹, Zhou Ying², Liu Fanglan¹

¹School of Medical Technology, Jiangxi Medical College, Shangrao 334000, China; ²TCM Department, Shangrao People's Hospital, Shangrao 334000, China

Online:2023-01-01 Published:2023-01-27
Contact: Gao Jianhua, Email: sky879100@163.com
Supported by:
Project Supported by Science and Technology Plan of Jiangxi Provincial Health Commission (202141025)

摘要/Abstract

摘要：

目的　探讨不同给药方法对多囊卵巢综合征（PCOS）患者排卵治疗的临床效果。方法　回顾性分析2019年6月至2021年12月在江西医学高等专科学校第一附属医院接受控制性促排卵（COH）治疗的PCOS患者124例（共333个COH周期），患者年龄26～39岁、平均年龄30.6岁，不育时间3～8年、平均不育时间4.6年。将患者根据不同给药方法分为研究组和对照组，其中分次给药组为研究组，共61例，162个周期；1次给药组为对照组，共63例，171个周期。两组患者均采用盐酸二甲双胍缓释片、曲格列酮、来曲唑、促卵泡激素（FSH）、尿促性腺激素（HMG）和人绒毛膜促性腺激素（HCG）多种药物联合治疗方案。比较两组治疗方案的平均周期用药量、成熟卵泡数、临床妊娠率及卵巢过度刺激综合征（OHSS）发生率。采用χ²检验或Fisher确切概率法。结果　研究组的平均周期用药量17.5支、临床妊娠率42.6%（26/61），高于对照组的14.4支平均周期用药量及25.4%（16/63）的临床妊娠率，而平均每个周期获得的成熟卵泡数2.11个及OHSS发生率3.3%（2/61），低于对照组的3.43个及15.9%（10/63），差异均有统计学意义（均P<0.05）。结论　分次给药在PCOS患者诱发排卵治疗中可提高临床妊娠率，并降低OHSS发生率。

关键词:

多囊卵巢综合征, 控制性促排卵, 卵巢过度刺激综合征, 鹿特丹共识

Abstract:

Objective　To explore the clinical effects of different medication methods on ovulation in patients with polycystic ovary syndrome (PCOS). Methods　A retrospective analysis was made on 124 PCOS patients [333 COH (controlled ovarian hyperstimulation) cycles in total] who received COH treatment in The First Affiliated Hospital of Jiangxi Medical College from June 2019 to December 2021. The patients' age ranged from 26 to 39 years old, with an average of 30.6 years old. The duration of infertility ranged from 3 to 8 years, with an average of 4.6 years. The patients were divided into a study group and a control group according to different medication methods. The 61 cases (162 cycles) in the study group received divided medication, and the 63 cases (171 cycles) in the control group received one-time medication. Both groups were treated with metformin hydrochloride sustained-release tablets, troglitazone, letrozole, follicle-stimulating hormone (FSH), urinary gonadotropin (HMG), and human chorionic gonadotropin (HCG). The average dose per cycle, the number of mature follicles, the clinical pregnancy rate, and the incidence of ovarian hyperstimulation syndrome (OHSS) were compared between the two groups. χ² test or Fisher exact probability method were used. Results　The average dose per cycle was 17.5 pills and the clinical pregnancy rate was 42.6% (26/61) in the study group, which were higher than 14.4 pills and 25.4%(16/63) in the control group; the average number of mature follicles obtained per cycle was 2.11 and the incidence of OHSS was 3.3% (2/61), which were lower than 3.43 and 15.9% (10/63) in the control group; there were statistically significant differences (all P<0.05). Conclusion　The divided medication method can improve the clinical pregnancy rate and reduce the incidence of OHSS in the ovulation induction for PCOS patients.

Key words:

Polycystic ovarian syndrome, Controlled ovarian hyperstimulation, Ovarian hyperstimulation syndrome, Rotterdam criteria

高建华王钏占明周莹刘芳兰.

不同给药方法在多囊卵巢综合征促孕治疗中的效果研究 [J]. 国际医药卫生导报, 2023, 29(1): 74-.

Gao Jianhua, Wang Chuan, Zhan Ming, Zhou Ying, Liu Fanglan.

Study on the effects of different medication methods in the promoting pregnancy treatment of polycystic ovary syndrome [J]. International Medicine and Health Guidance News, 2023, 29(1): 74-.

参考文献

[1] Joham AE, Norman RJ, Stener-Victorin E, et al. Polycystic ovary syndrome[J].Lancet Diabetes Endocrinol,2022,10(9):668-680. DOI:DOI:10.1016/S2213-8587(22)00163-2.
[2] McCartney CR, Marshall JC. CLINICAL PRACTICE. Polycystic ovary syndrome[J]. N Engl J Med,2016,375(1):54-64. DOI:10.1056/NEJMcp1514916.
[3] Moran LJ, Norman RJ, Teede HJ. Metabolic risk in PCOS: phenotype and adiposity impact[J]. Trends Endocrinol Metab,2015,26(3):136-143. DOI:10.1016/j.tem.2014. 12.003.
[4] 罗丽兰.不孕与不育[M].2版.北京:人民卫生出版社,2011:127.
[5] Homburg R. Polycystic ovary syndrome[J]. Best Pract Res Clin Obstet Gynaecol,2008,22(2):261-274. DOI:10.1016/j.bpobgyn.2007.07.009.
[6] Nastri CO, Teixeira DM, Moroni RM, et al. Ovarian hyperstimulation syndrome: pathophysiology, staging, prediction and prevention[J]. Ultrasound Obstet Gynecol,2015,45(4):377-393. DOI:10.1002/uog.14684.
[7] 吴潇浛,黄筱金,陈曼萍. 172个放弃治疗的促排卵周期的临床后果分析[J]. 医学综述,2015,21(5):955-956. DOI:10.3969/j.issn.1006-2084.2015.05.077.
[8] Nardo LG, Fleming R, Howles CM, et al. Conventional ovarian stimulation no longer exists: welcome to the age of individualized ovarian stimulation[J]. Reprod Biomed Online,2011,23(2):141-148. DOI:10.1016/j.rbmo.2011. 05.008.
[9] Jahan Z, Wing KE. Polycystic ovary syndrome and its relationship with infertility and its management[J]. J Bangladesh Coll Phys Surg,2021,39(1):53-58. DOI:10.3329/jbcps.v39i1.50458.
[10] 孙海云,胡玉宏,徐水芳. 利拉鲁肽联合二甲双胍对多囊卵巢综合征患者卵巢功能的影响[J]. 现代药物与临床,2021,36(8):1654-1658. DOI:10.7501/j.issn.1674-5515.2021. 08.021.
[11] 邢思思. 来曲唑联合克罗米芬治疗多囊卵巢综合征的临床疗效分析[J]. 中国实用医药,2021,16(26):149-151. DOI:10.14163/j.cnki.11-5547/r.2021.26.056.
[12] 张静芳. 二甲双胍联合炔雌醇环丙孕酮治疗多囊卵巢综合征患者的临床疗效及安全性[J]. 临床合理用药杂志,2022,15(15):146-148. DOI:10.15887/j.cnki.13-1389/r.2022. 15.046.
[13] Wang R, Mol BW. The Rotterdam criteria for polycystic ovary syndrome: evidence-based criteria?[J]. Hum Reprod,2017,32(2):261-264. DOI:10.1093/humrep/dew287.
[14] Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome[J]. Nat Rev Dis Primers,2016,2:16057. DOI:10.1038/nrdp.2016.57.
[15] Dumesic DA, Oberfield SE, Stener-Victorin E, et al. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome[J]. Endocr Rev,2015,36(5):487-525. DOI:10.1210/er.2015-1018.
[16] Franks S. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria[J]. J Clin Endocrinol Metab,2006,91(3):786-789. DOI:10.1210/jc.2005-2501.
[17] Azziz R, Carmina E, Dewailly D, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline[J]. J Clin Endocrinol Metab,2006,91(11):4237-4245. DOI:10.1210/jc.2006-0178.
[18] Azziz R. Polycystic ovary syndrome[J]. Obstet Gynecol,2018,132(2):321-336. DOI:10.1097/AOG.0000000000002698.
[19] Moore AM, Campbell RE. Polycystic ovary syndrome: Understanding the role of the brain[J]. Front Neuroendocrinol,2017,46:1-14. DOI:10.1016/j.yfrne.2017.05.002.
[20] Azziz R. PCOS in 2015: new insights into the genetics of polycystic ovary syndrome[J]. Nat Rev Endocrinol,2016,12(2):74-75. DOI:10.1038/nrendo.2015.230.
[21] Lee H, Oh JY, Sung YA, et al. Genome-wide association study identified new susceptibility loci for polycystic ovary syndrome[J]. Hum Reprod,2015,30(3):723-731. DOI:10.1093/humrep/deu352.
[22] Hayes MG, Urbanek M, Ehrmann DA, et al. Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations[J]. Nat Commun,2015,6(1):7502. DOI:10.1038/ncomms8502.
[23] Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries[J]. Am J Obstet Gynecol,1935,29(2):181-191. DOI:10.1016/S0002-9378(15)30642-6.
[24] Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report[J]. Fertil Steril,2009,91(2):456-488. DOI:10.1016/j.fertnstert.2008. 06.035.
[25] Hart R, Doherty DA. The potential implications of a PCOS diagnosis on a woman's long-term health using data linkage[J]. J Clin Endocrinol Metab,2015,100(3):911-919. DOI:10.1210/jc.2014-3886.
[26] Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment[J]. Nat Rev Endocrinol,2018,14(5):270-284. DOI:10.1038/nrendo. 2018.24.
[27] Mishra A, Younossi ZM. Epidemiology and natural history of non-alcoholic fatty liver disease[J]. J Clin Exp Hepatol,2012,2(2):135-144. DOI:10.1016/S0973-6883(12)60102-9.
[28] Khan U. Polycystic ovary syndrome in adolescents[J]. J Pediatr Adolesc Gynecol,2007,20(2):101-104. DOI:10.1016/j.jpag.2007.01.001.
[29] Rothenberg SS, Beverley R, Barnard E, et al. Polycystic ovary syndrome in adolescents[J]. Best Pract Res Clin Obstet Gynaecol,2018,48:103-114. DOI:10.1016/j.bpobgyn.2017.08.008.
[30] Witchel SF, Oberfield S, Rosenfield RL, et al. The diagnosis of polycystic ovary syndrome during adolescence[J]. Horm Res Paediatr,2015,83(6):376-389. DOI:10.1159/000375530.
[31] Rosenfield RL. The diagnosis of polycystic ovary syndrome in adolescents[J]. Pediatrics,2015,136(6):1154-1165. DOI:10.1542/peds.2015-1430.

不同给药方法在多囊卵巢综合征促孕治疗中的效果研究

Study on the effects of different medication methods in the promoting pregnancy treatment of polycystic ovary syndrome

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics